Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Allogeneic EPCs in Critical Limb Ischemia
NCT06359912Phase 1Recruiting
- Sponsor
- Allife Medical Science and Technology
- Start
- Apr 2024
- Primary completion
- Apr 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ALF-202 in critical limb ischemia (CLI) (2 arms), sponsored by Allife Medical Science and Technology. Primary endpoint: Adverse events at 1 year. Started Apr 2024; status: recruiting.
02
Drugs
ALF-202
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT06359912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06359912.